Serum glucose, cholesterol and blood pressure levels in Japanese type 1 and 2 diabetic patients: BioBank Japan.
BACKGROUND
Evidence of characteristics of Japanese patients with diabetes from a large-scale population is necessary. Few studies have compared glycaemic controls, complications and comorbidities between type 1 and 2 diabetic patients. This paper focuses on illustrating a clinical picture of Japanese diabetic patients and comparing glycaemic control and prognoses between type 1 and 2 diabetes using multi-institutional data.


METHODS
The BioBank Japan Project enrolled adult type 1 and 2 diabetic patients between fiscal years 2003 and 2007. We have presented characteristics, controls of serum glucose, cholesterol and blood pressure, prevalence of complications and comorbidities and survival curves. We have also shown glycaemic controls according to various individual profiles of diabetic patients.


RESULTS
A total of 558 type 1 diabetic patients and 30,834 type 2 diabetic patients participated in this study. The mean glycated haemoglobin A1c was higher in type 1 diabetes than in type 2 diabetes. In the type 1 diabetic patients, the glycated haemoglobin A1c had no consistent trend according to age and body mass index. The Kaplan-Meier estimates represented a longer survival time from baseline with type 1 diabetes than with type 2 diabetes. Compared with type 1 diabetic patients, type 2 diabetic patients had double the prevalence of macrovascular complications.


CONCLUSIONS
This work has revealed detailed plasma glucose levels of type 1 and 2 diabetic patients according to age, body mass index, blood pressure, serum cholesterol levels and smoking and drinking habits. Our data have also shown that the prognosis is worse for type 2 diabetes than for type 1 diabetes in Japan.
Department of Health Sciences, University of Yamanashi, Yamanashi, Japan. Electronic address: hyokomichi@yamanashi.ac.jp.
Hiroshi
H
Yokomichi
Department of Public Policy, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Akiko
A
Nagai
Laboratory of Genome Technology, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Makoto
M
Hirata
Hisayama Research Institute for Lifestyle Diseases, Fukuoka, Japan.
Yutaka
Y
Kiyohara
Department of Public Policy, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Kaori
K
Muto
Department of Epidemiology and Public Health, Graduate School of Medical Sciences, Kyushu University, Fukuoka City, Fukuoka, Japan.
Toshiharu
T
Ninomiya
Laboratory of Molecular Medicine, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Koichi
K
Matsuda
Laboratory for Statistical Analysis, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.
Yoichiro
Y
Kamatani
Department of Public Health, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
Akiko
A
Tamakoshi
RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.
Michiaki
M
Kubo
Laboratory of Molecular Medicine, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Yusuke
Y
Nakamura
Department of Health Sciences, University of Yamanashi, Yamanashi, Japan.
Zentaro
Z
Yamagata
D000328:Adult; D000368:Aged; D018070:Biological Specimen Banks; D001786:Blood Glucose / Q000032:analysis*; D001794:Blood Pressure / Q000502:physiology*; D002784:Cholesterol / Q000097:blood*; D015897:Comorbidity; D048909:Diabetes Complications / Q000453:epidemiology; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000453:epidemiology / Q000503:physiopathology; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000453:epidemiology / Q000503:physiopathology; D005260:Female; D006801:Humans; D007564:Japan / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D016019:Survival Analysis
D001786:Blood Glucose; D002784:Cholesterol
Comorbidity; Diabetes; Glycated haemoglobin A1c; Kaplan–Meier estimate; Smoking